<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0122646</article-id>
<article-id pub-id-type="publisher-id">PONE-D-14-57504</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">Bisphosphonates and Cardiovascular Events</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Kim</surname>
<given-names>Dae Hyun</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
<xref rid="cor001" ref-type="corresp">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Rogers</surname>
<given-names>James R.</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Fulchino</surname>
<given-names>Lisa A.</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kim</surname>
<given-names>Caroline A.</given-names>
</name>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Solomon</surname>
<given-names>Daniel H.</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kim</surname>
<given-names>Seoyoung C.</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Pizzi</surname>
<given-names>Carmine</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Bologna, ITALY</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have read the journal's policy and have the following competing interests: * DHK is supported by a KL2 Medical Research Investigator Training award from Harvard Catalyst / The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Award 1KL2 TR001100-01). DHK provides paid consultative services on geriatrics care to the Alosa Foundation, a nonprofit educational organization with no relationship to any drug or device manufacturers. * CAK is supported by a T32 Cardiovascular Research Training award from National Heart, Lung, and Blood Institute (NIH Award, T32 HL007374-35). * DHS is supported by the NIH grants K24-AR055989, P60-AR047782, and R01-AR056215. Solomon receives research grants from Amgen, Lilly and Pfizer. He serves in unpaid roles on studies sponsored by Pfizer, Novartis, Lilly, and Bristol Myers Squibb. He also receives royalties from <ext-link ext-link-type="uri" xlink:href="http://UpToDate.com" xlink:type="simple">UpToDate.com</ext-link>. * SCK is supported by the NIH grant K23 AR059677. She received research support from Pfizer and Lilly". This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: DHK SCK. Analyzed the data: DHK. Wrote the paper: DHK JRR LAF CAK DHS SCK. Acquisition of Data: DHK JRR LAF CAK SCK. Interpretation of Data: DHK JRR LAF CAK DHS SCK. Administrative, Technical, or Material Support: JRR LAF CAK SCK.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">dkim12@partners.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>4</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>4</issue>
<elocation-id>e0122646</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>12</month>
<year>2014</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>2</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Kim et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0122646" xlink:type="simple"/>
<abstract>
<sec id="sec001">
<title>Background and Objectives</title>
<p>Some evidence suggests that bisphosphonates may reduce atherosclerosis, while concerns have been raised about atrial fibrillation. We conducted a meta-analysis to determine the effects of bisphosphonates on total adverse cardiovascular (CV) events, atrial fibrillation, myocardial infarction (MI), stroke, and CV death in adults with or at risk for low bone mass.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>A systematic search of MEDLINE and EMBASE through July 2014 identified 58 randomized controlled trials with longer than 6 months in duration that reported CV events. Absolute risks and the Mantel-Haenszel fixed-effects odds ratios (ORs) and 95% confidence intervals (CIs) of total CV events, atrial fibrillation, MI, stroke, and CV death were estimated. Subgroup analyses by follow-up duration, population characteristics, bisphosphonate types, and route were performed.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Absolute risks over 25–36 months in bisphosphonate-treated versus control patients were 6.5% versus 6.2% for total CV events; 1.4% versus 1.5% for atrial fibrillation; 1.0% versus 1.2% for MI; 1.6% versus 1.9% for stroke; and 1.5% versus 1.4% for CV death. Bisphosphonate treatment up to 36 months did not have any significant effects on total CV events (14 trials; ORs [95% CI]: 0.98 [0.84–1.14]; <italic>I<sup>2</sup></italic> = 0.0%), atrial fibrillation (41 trials; 1.08 [0.92–1.25]; <italic>I<sup>2</sup></italic> = 0.0%), MI (10 trials; 0.96 [0.69–1.34]; <italic>I<sup>2</sup></italic> = 0.0%), stroke (10 trials; 0.99 [0.82–1.19]; <italic>I<sup>2</sup></italic> = 5.8%), and CV death (14 trials; 0.88 [0.72–1.07]; <italic>I<sup>2</sup></italic> = 0.0%) with little between-study heterogeneity. The risk of atrial fibrillation appears to be modestly elevated for zoledronic acid (6 trials; 1.24 [0.96–1.61]; <italic>I<sup>2</sup></italic> = 0.0%), not for oral bisphosphonates (26 trials; 1.02 [0.83–1.24]; <italic>I<sup>2</sup></italic> = 0.0%). The CV effects did not vary by subgroups or study quality.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>Bisphosphonates do not have beneficial or harmful effects on atherosclerotic CV events, but zoledronic acid may modestly increase the risk of atrial fibrillation. Given the large reduction in fractures with bisphosphonates, changes in osteoporosis treatment decision due to CV risk are not justified.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The authors received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<page-count count="13"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Over 30 million older adults in the United States have low bone mass.[<xref rid="pone.0122646.ref001" ref-type="bibr">1</xref>] These individuals have greater burden of vascular calcification and rapidly progressive atherosclerosis compared with those with normal bone mass.[<xref rid="pone.0122646.ref002" ref-type="bibr">2</xref>–<xref rid="pone.0122646.ref005" ref-type="bibr">5</xref>] Every 1 standard deviation decrease in bone mineral density is associated with 1.3 to 2.3-fold increase in cardiovascular (CV) mortality.[<xref rid="pone.0122646.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0122646.ref008" ref-type="bibr">8</xref>] In fact, emerging evidence indicates that vascular calcification is an actively regulated process that shares several biological mechanisms with bone mineralization.[<xref rid="pone.0122646.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0122646.ref011" ref-type="bibr">11</xref>] In vitro and in vivo studies have demonstrated the potential of vascular cells to undergo osteoblastic differentiation.[<xref rid="pone.0122646.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0122646.ref013" ref-type="bibr">13</xref>] Likewise, osteoclast-like cells have been found in the human calcified atherosclerotic lesions.[<xref rid="pone.0122646.ref014" ref-type="bibr">14</xref>] Bone matrix proteins and regulatory factors appear to regulate vascular calcification.[<xref rid="pone.0122646.ref011" ref-type="bibr">11</xref>]</p>
<p>Understanding the biological similarities between vascular calcification and bone mineralization has led to the idea that bisphosphonates may influence vascular calcification. In addition to inhibiting bone resorption, evidence suggests that bisphosphonates may inhibit atherosclerosis and vascular calcification. In several small-scale clinical trials, etidronate modestly improved surrogate endpoints of atherosclerosis, such as carotid intima media thickness,[<xref rid="pone.0122646.ref015" ref-type="bibr">15</xref>] coronary artery calcium,[<xref rid="pone.0122646.ref016" ref-type="bibr">16</xref>] and aortic calcification.[<xref rid="pone.0122646.ref017" ref-type="bibr">17</xref>] However, bisphosphonate trials designed to study clinical CV endpoints are currently lacking. Epidemiologic studies found a lower risk of myocardial infarction (MI) or stroke among bisphosphonate users compared with non-users.[<xref rid="pone.0122646.ref018" ref-type="bibr">18</xref>–<xref rid="pone.0122646.ref020" ref-type="bibr">20</xref>] While such epidemiologic evidence suggests that bisphosphonates may protect against atherosclerotic CV events,[<xref rid="pone.0122646.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0122646.ref022" ref-type="bibr">22</xref>] healthy user bias cannot be excluded. Moreover, a possible increase in atrial fibrillation associated with bisphosphonates[<xref rid="pone.0122646.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0122646.ref024" ref-type="bibr">24</xref>] may counteract the potential benefits on atherosclerotic CV disease.</p>
<p>In the absence of any bisphosphonate trial sufficiently powered to examine clinical CV events, a meta-analysis of previously conducted trials would be a useful approach to explore potential CV effects of bisphosphonates. Prior reviews have focused on atrial fibrillation[<xref rid="pone.0122646.ref025" ref-type="bibr">25</xref>–<xref rid="pone.0122646.ref034" ref-type="bibr">34</xref>] or a single bisphosphonate agent.[<xref rid="pone.0122646.ref031" ref-type="bibr">31</xref>–<xref rid="pone.0122646.ref033" ref-type="bibr">33</xref>] We conducted a meta-analysis of randomized controlled trials (RCTs) to determine the effects of bisphosphonates versus placebo or no treatment control on total CV events, atrial fibrillation, MI, stroke, and CV mortality in adults with or at risk for low bone mass.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec007">
<title>Data Sources and Systematic Search</title>
<p>This meta-analysis was conducted in accordance with PRISMA guidelines (<ext-link ext-link-type="uri" xlink:href="http://www.equator-network.org/reporting-guidelines/prisma/" xlink:type="simple">http://www.equator-network.org/reporting-guidelines/prisma/</ext-link>; review protocol available from authors upon request). We performed a systematic search of MEDLINE and EMBASE, with no language restriction, from inception through July 28, 2014, to identify RCTs of bisphosphonates (see Text 1 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref> for systematic search strategy). Because adverse events were incompletely indexed in MEDLINE and EMBASE,[<xref rid="pone.0122646.ref035" ref-type="bibr">35</xref>] we did not use any keywords for CV events in our search. Instead, we manually looked for information on adverse CV events (total adverse CV events, atrial fibrillation, MI, stroke, and CV mortality) in the full text. We searched references in published reviews[<xref rid="pone.0122646.ref025" ref-type="bibr">25</xref>–<xref rid="pone.0122646.ref034" ref-type="bibr">34</xref>] to obtain additional CV event data that were unavailable in the original publications. We included 2 pooled analyses by Lewiecki et al. (4 trials of ibandronate)[<xref rid="pone.0122646.ref032" ref-type="bibr">32</xref>] and Karam et al. (6 trials of risedronate).[<xref rid="pone.0122646.ref033" ref-type="bibr">33</xref>] We also contacted the authors of publications within the recent 10 years that included at least 1000 participants, but our attempt did not yield any additional information. Because this was a meta-analysis, ethics approval was not required.</p>
</sec>
<sec id="sec008">
<title>Study Selection</title>
<p>Trained research assistants (JRR and LAF) independently evaluated all identified publications for their eligibility and any disagreements were resolved through discussion with investigators (DHK and SCK). A publication was considered eligible if it originated from RCTs that compared oral or intravenous bisphosphonate versus placebo or no treatment control in adults. We excluded a publication for the following reasons: 1) not RCT of oral or intravenous bisphosphonate versus no bisphosphonate (e.g. no randomization, cross-over design, open-label extension study, or lack of control group); 2) the follow-up duration of 6 months or shorter; 3) conducted in specific populations that might have a different risk of CV events (e.g. patients with cancer, transplant, or human immunodeficiency virus infection, or children); 4) study protocols, commentaries, reviews, or non-human studies; 5) no data on total CV events, atrial fibrillation, MI, stroke, and CV mortality.</p>
</sec>
<sec id="sec009">
<title>Data Extraction and Assessment of Study Quality</title>
<p>Using a standardized form, 3 reviewers (JRR, LAF, and DHK) extracted the following information from each study: bisphosphonate (dose, frequency, and route), sample size, mean age (years), female (%), mean weight (kg), mean body mass index (kg/m<sup>2</sup>), characteristics of study population (osteoporosis or other at-risk conditions for osteoporosis, such as osteopenia, steroid use, or chronic inflammatory disease), follow-up duration (months), and number of CV events, including serious atrial fibrillation events, defined as death, disability, hospitalization, or requiring interventions related to atrial fibrillation. Three investigators (DHK, CAK, and SCK) confirmed the accuracy of data collection and assessed the study quality as adequate or inadequate, according to the following standards: 1) generation of random sequence; 2) concealment of randomization; 3) blinding of participants and study personnel; 4) blinding of outcome assessors; 5) loss to follow-up (adequate if loss to follow-up was less than 20%); 6) completeness of CV event reporting (complete if the number of atrial fibrillation, MI, stroke, and CV death was reported); 7) ascertainment of CV events (adequate if CV events were adjudicated based on medical records). When there was insufficient information, it was considered inadequate.</p>
</sec>
<sec id="sec010">
<title>Data Synthesis and Analysis</title>
<p>For each of CV events, we combined individual study results to calculate the pooled odds ratio (OR) and 95% confidence interval (CI) using the Mantel-Haenszel fixed-effects method without zero-cell correction. This method is the least biased method in analyzing sparse events when there is large imbalance in the treatment group size.[<xref rid="pone.0122646.ref036" ref-type="bibr">36</xref>] Between-study heterogeneity was assessed using the Cochran’s <italic>Q</italic> statistic and <italic>I</italic><sup><italic>2</italic></sup> statistic.[<xref rid="pone.0122646.ref037" ref-type="bibr">37</xref>] Pre-specified subgroup meta-analyses and meta-regression were performed to evaluate whether the CV effects of bisphosphonates differed by follow-up duration (≤12, 13–24, 25–36, &gt;36 months), age (&lt;60, 60–69, ≥70 years), sex (female, male, or both), population characteristics (osteoporosis or at-risk conditions for osteoporosis), bisphosphonate types (alendronate, ibandronate, risedronate, zoledronic acid, or others), and route (oral or intravenous). We summarized the risk of CV events by bisphosphonate dose, but did not perform a formal dose-response analysis due to limited numbers of trials that reported each outcome.</p>
<p>As sensitivity analyses, we assessed the influence of study quality standards on the pooled OR. We also examined whether the pooled ORs were due to any single influential study by repeating meta-analyses after excluding 1 study at a time. Since CV events were not reported in all trials, we investigated the possibility of publication bias using the Begg adjusted rank correlation test,[<xref rid="pone.0122646.ref038" ref-type="bibr">38</xref>] the Egger regression test,[<xref rid="pone.0122646.ref039" ref-type="bibr">39</xref>] and the trim-and-fill method (Stata METATRIM command). All analyses were performed in Stata version 11 (StataCorp, College Station, TX). A 2-sided p-value &lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<sec id="sec012">
<title>Characteristics of Included Studies</title>
<p>A total of 58 RCTs reported at least 1 CV outcome (<xref rid="pone.0122646.g001" ref-type="fig">Fig 1</xref>): total adverse CV events (14 trials), atrial fibrillation (41 trials), MI (10 trials), stroke (10 trials), and CV mortality (14 trials). Compared with 112 trials without CV event data, 58 trials with CV event data had larger sample size (median: 158 versus 37 in bisphosphonate group and 92 versus 35 in control group), older participants (mean age: 63.0 versus 58.8 years), and longer follow-up time than trials without CV event data (median: 24 versus 12 months) (Table 1 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>). Most trials included adults who were generally healthy and without multiple comorbidities (Table 2 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>).</p>
<fig id="pone.0122646.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122646.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Selection of Randomized Controlled Trials of Bisphosphonates for Meta-Analysis.</title>
<p>Abbreviations: BIS, bisphosphonate; CTR, control; HIV, human immunodeficiency virus; RCT, randomized controlled trial</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122646.g001" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec013">
<title>Assessment of Study Quality</title>
<p>The quality of the 58 included trials was summarized in Fig 1 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref> (see Table 3 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref> for individual study quality). The number of trials that satisfied each quality standard varied widely: generation of random sequence (28%), concealment of allocation (16%), blinding of participants and personnel (93%), blinding of outcome assessors (95%), adequacy of follow-up (74%), completeness of CV event reporting (5%), and ascertainment of CV events (5%).</p>
</sec>
<sec id="sec014">
<title>Bisphosphonates and Total Adverse CV Events</title>
<p>Total adverse CV event data were available in 14 trials that included 5822 bisphosphonate-treated and 3564 control patients. The absolute risk was 6.5% in bisphosphonate-treated patients versus 6.2% in control patients over 25–36 months. The Mantel-Haenszel pooled OR (95% CI) was 0.98 (0.84, 1.14) with little between-study heterogeneity (<italic>I</italic><sup><italic>2</italic></sup> = 0.0%) (<xref rid="pone.0122646.g002" ref-type="fig">Fig 2</xref>). The pooled ORs did not differ across subgroups defined by the follow-up duration, mean age, sex, population characteristics, bisphosphonate types, and administration route (Fig 2 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>).</p>
<fig id="pone.0122646.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122646.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Meta-Analysis of Total Adverse Cardiovascular Events Associated with Use of Bisphosphonates.</title>
<p>Abbreviations: CI, confidence interval; CV, cardiovascular; EPIC, Early Postmenopausal Intervention Cohort study; IVF, IntraVenous Fracture study; M-H, Mantel Haenszel; OR, odds ratio; VERT-MN, Vertebral Efficacy with Risedronate Therapy Multinational Study</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122646.g002" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Bisphosphonates and Atrial Fibrillation</title>
<p>Data on atrial fibrillation were available in 41 trials that included 31460 bisphosphonate-treated and 19752 control patients. The absolute risk was 1.4% in bisphosphonate-treated patients and 1.5% in control patients over 25–36 months. The Mantel-Haenszel pooled OR (95% CI) was 1.08 (0.92, 1.25) with little between-study heterogeneity (<italic>I</italic><sup><italic>2</italic></sup> = 0.0%) (<xref rid="pone.0122646.g003" ref-type="fig">Fig 3</xref>). There was no statistically significant variation in the pooled ORs across pre-defined subgroups (Fig 3 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>). However, the risk seemed modestly elevated for zoledronic acid (pooled OR: 1.24; 95% CI: 0.96, 1.61) (Fig 3 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>).</p>
<fig id="pone.0122646.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122646.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Meta-Analysis of Atrial Fibrillation Associated with Use of Bisphosphonates.</title>
<p>* Abbreviations: CI, confidence interval; EPIC, Early Postmenopausal Intervention Cohort study; FIT, Fracture Intervention Trial; FOSIT, Fosamax International Trial; HORIZON-PFT, the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial; HORIZON-RFT, the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial; M-H, Mantel Haenszel; OR, odds ratio. * Lewiecki (2010) et al. included data from 4 trials of ibandronate. Karam (2007) et al. included data from 6 trials of risedronate. Individual study data were not available.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122646.g003" position="float" xlink:type="simple"/>
</fig>
<p>When the analysis was restricted to serious atrial fibrillation events available in phase 3 trials,[<xref rid="pone.0122646.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0122646.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0122646.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0122646.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0122646.ref040" ref-type="bibr">40</xref>] there was a modestly increased risk (pooled OR: 1.41; 95% CI: 1.10, 1.81) with large between-study heterogeneity (<italic>I</italic><sup><italic>2</italic></sup> = 78.4%). The elevated risk and heterogeneity were mainly driven by a single study of zoledronic acid[<xref rid="pone.0122646.ref023" ref-type="bibr">23</xref>]: the pooled OR (95% CI) after excluding this study was 1.19 (0.90, 1.58) with little between-study heterogeneity (<italic>I</italic><sup><italic>2</italic></sup> = 0.0%).</p>
</sec>
<sec id="sec016">
<title>Bisphosphonates and MI, Stroke, and CV Death</title>
<p>The risks of MI, stroke, and CV death over 25–36 months in bisphosphonate-treated patients and control patients were low (MI: 1.0% versus 1.2%; stroke: 1.6% versus 1.9%; and CV death: 1.5% versus 1.4%) and similar between the treated and placebo patients (Figs <xref rid="pone.0122646.g004" ref-type="fig">4</xref> and <xref rid="pone.0122646.g005" ref-type="fig">5</xref>). There was no statistically significant difference in the pooled ORs across the pre-defined subgroups (Figs 4, 5, and 6 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>).</p>
<fig id="pone.0122646.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122646.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Meta-Analysis of Myocardial Infarction and Stroke with Use of Bisphosphonates.</title>
<p>* Abbreviations: CI, confidence interval; HORIZON-PFT, the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial; HORIZON-RFT, the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial; M-H, Mantel Haenszel; OR, odds ratio. * Karam (2007) et al. included data from 6 trials of risedronate. Individual study data were not available.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122646.g004" position="float" xlink:type="simple"/>
</fig>
<fig id="pone.0122646.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122646.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Meta-Analysis of Cardiovascular Mortality with Use of Bisphosphonates.</title>
<p>* Abbreviations: CI, confidence interval; CV, cardiovascular; HORIZON-PFT, the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial; HORIZON-RFT, the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial; M-H, Mantel Haenszel; OR, odds ratio. * Karam (2007) et al. included data from 6 trials of risedronate. Individual study data were not available.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122646.g005" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec017">
<title>Sensitivity Analyses</title>
<p>There was no indication of dose-response relationship between bisphosphonate dose and each CV event (Table 4 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>). The quality standards had little effects on the pooled ORs (Table 5 in <xref rid="pone.0122646.s002" ref-type="supplementary-material">S1 File</xref>). Except serious atrial fibrillation events, our results changed minimally when we re-estimated the pooled ORs after excluding 1 trial at a time. Finally, we did not find any evidence of publication bias by the Begg adjusted rank correlation test and the Egger regression test for all 5 outcomes (data not shown). The trim-and-fill method made little difference in the pooled OR (95% CI): 0.98 (0.83, 1.14) for total CV events; 1.08 (0.93, 1.26) for atrial fibrillation; 0.82 (0.59, 1.15) for MI; 0.99 (0.82, 1.19) for stroke; and 0.87 (0.72, 1.06) for CV death. These results suggest that selective reporting of CV events among the trials was unlikely.</p>
</sec>
</sec>
<sec id="sec018" sec-type="conclusions">
<title>Discussion</title>
<p>Our meta-analysis of 58 RCTs did not find any indication that treatment with commonly prescribed bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid) up to 36 months or longer would have any clinically important effects on atherosclerotic CV events among individuals with or at risk for low bone mass. The risk of atrial fibrillation appears to be modestly elevated for intravenous zoledronic acid, although the evidence was inconclusive. These results contradict the findings from previous observational studies[<xref rid="pone.0122646.ref018" ref-type="bibr">18</xref>–<xref rid="pone.0122646.ref020" ref-type="bibr">20</xref>] and clinical trials of surrogate endpoints (e.g. carotid intima media thickness,[<xref rid="pone.0122646.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0122646.ref041" ref-type="bibr">41</xref>] coronary artery calcium,[<xref rid="pone.0122646.ref016" ref-type="bibr">16</xref>] and aortic calcification[<xref rid="pone.0122646.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0122646.ref042" ref-type="bibr">42</xref>]) that suggest possible benefits of bisphosphonates on atherosclerotic CV events.</p>
<p>Potential mechanisms by which bisphosphonates may reduce atherosclerotic CV events include inducing macrophage apoptosis, preventing foam cell formation, lowering cholesterol levels by inhibiting mevalonate pathway, and anti-inflammatory effect.[<xref rid="pone.0122646.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0122646.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0122646.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0122646.ref022" ref-type="bibr">22</xref>] Bisphosphonate prevented development or decreased the extent of atherosclerosis in animal models.[<xref rid="pone.0122646.ref043" ref-type="bibr">43</xref>–<xref rid="pone.0122646.ref045" ref-type="bibr">45</xref>] In humans, etidronate has been studied in several trials as an inhibitor of vascular calcification. It decreased carotid intima media thickness (by 0.038 mm),[<xref rid="pone.0122646.ref015" ref-type="bibr">15</xref>] coronary artery calcium score (by 372 mm<sup>3</sup>),[<xref rid="pone.0122646.ref016" ref-type="bibr">16</xref>] and aortic calcification (by 14–15%)[<xref rid="pone.0122646.ref017" ref-type="bibr">17</xref>] in high-risk patients over 9–12 months. Such reduction in carotid intima media thickness was comparable to or greater than the effects observed from some statins: pitavastatin decreased carotid intima media thickness by 0.024 mm/year in patients with known atherosclerosis,[<xref rid="pone.0122646.ref046" ref-type="bibr">46</xref>] while rosuvastatin decreased carotid intima media thickness by 0.0014 mm/year among low-risk individuals.[<xref rid="pone.0122646.ref047" ref-type="bibr">47</xref>] The evidence on other bisphosphonates is mixed. Alendronate reduced carotid intima media thickness (by 0.025 mm)[<xref rid="pone.0122646.ref041" ref-type="bibr">41</xref>] in hemodialysis patients, but not in patients with chronic kidney disease.[<xref rid="pone.0122646.ref048" ref-type="bibr">48</xref>] While a 36-month ibandronate treatment did not alter the progression of aortic calcification,[<xref rid="pone.0122646.ref049" ref-type="bibr">49</xref>] risedronate slowed progression in 12 months.[<xref rid="pone.0122646.ref042" ref-type="bibr">42</xref>] Despite the beneficial effects on surrogate endpoints, we found no evidence of reduction in atherosclerotic CV events with bisphosphonates (as opposed to statins). Some evidence suggests that most benefits of statins result from plaque stabilization, rather than regression of atherosclerosis.[<xref rid="pone.0122646.ref050" ref-type="bibr">50</xref>] The effects of bisphosphonates on plaque stabilization remain unknown. Intravascular ultrasound may be more useful to assess the changes in plaque volume and characteristics.[<xref rid="pone.0122646.ref051" ref-type="bibr">51</xref>] It is also possible that CV protective effects may depend on different bisphosphonate agents. Etidronate, a non-nitrogen-containing bisphosphonate, is considered to be the most potent inhibitor of vascular calcification,[<xref rid="pone.0122646.ref021" ref-type="bibr">21</xref>] but our meta-analysis did not have a sufficient number of trials that evaluated etidronate.</p>
<p>Our findings on MI and stroke contradict the results from epidemiologic studies.[<xref rid="pone.0122646.ref018" ref-type="bibr">18</xref>–<xref rid="pone.0122646.ref020" ref-type="bibr">20</xref>] In the Taiwan National Health Insurance database, Kang et al. found 65% lower rate of MI and 21% lower rate of stroke over 2 years among patients who received at least 1 year of continuous treatment with bisphosphonates compared with patients with acute osteoporotic fracture who did not receive bisphosphonates during the follow-up period.[<xref rid="pone.0122646.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0122646.ref019" ref-type="bibr">19</xref>] In a cohort of rheumatoid arthritis patients, Wolfe et al. showed 28% lower rate of MI in ever-treated patients than never-treated patients.[<xref rid="pone.0122646.ref020" ref-type="bibr">20</xref>] Because patients who comply with long-term bisphosphonate treatment are more likely to have better health status and healthy behaviors than those who remain untreated during the study period, such comparison may result in more favorable findings for bisphosphonates. Due to such healthy user bias, observation studies may not be appropriate to address this question. This bias is minimal in our meta-analysis that only included RCTs.</p>
<p>Concerns exist about the risk of serious atrial fibrillation events associated with bisphosphonates,[<xref rid="pone.0122646.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0122646.ref024" ref-type="bibr">24</xref>] attributing altered intracellular ion concentration and pro-inflammatory, pro-fibrotic, and anti-angiogenic properties as potential mechanisms.[<xref rid="pone.0122646.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0122646.ref052" ref-type="bibr">52</xref>] Since these early reports,[<xref rid="pone.0122646.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0122646.ref024" ref-type="bibr">24</xref>] several meta-analyses of RCTs and observational studies have been conducted to assess the risk of atrial fibrillation associated with bisphosphonates. Despite similarities in the included source studies, the conclusions were inconsistent: some reviews found an increase risk of serious or any atrial fibrillation,[<xref rid="pone.0122646.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0122646.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0122646.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0122646.ref034" ref-type="bibr">34</xref>] whereas others did not.[<xref rid="pone.0122646.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0122646.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0122646.ref031" ref-type="bibr">31</xref>–<xref rid="pone.0122646.ref033" ref-type="bibr">33</xref>] In our meta-analysis that included the same phase 3 trials as previous meta-analyses,[<xref rid="pone.0122646.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0122646.ref034" ref-type="bibr">34</xref>] we found that the evidence was heterogeneous and the elevated risk was mainly driven by zoledronic acid.[<xref rid="pone.0122646.ref023" ref-type="bibr">23</xref>] The risk was not elevated for oral bisphosphonates. Recent meta-analyses by Sharma et al.[<xref rid="pone.0122646.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0122646.ref027" ref-type="bibr">27</xref>] found an elevated risk for any atrial fibrillation. However, their pooled relative risks were overestimated because they included unadjusted risks from non-randomized studies. Taken together, the body of evidence suggests that oral bisphosphonates have little effects on the risk of atrial fibrillation; the risk appears to be modestly elevated for intravenous zoledronic acid. The evidence for serious atrial fibrillation events is inconclusive: even if present, the absolute risk is small and the relative risk seems lower than previously perceived. No increased risk of stroke and CV death is also reassuring.</p>
<p>Our meta-analysis has several strengths. It is the most comprehensive and up-to-date summary of evidence on bisphosphonates and CV events that included the largest number of trials of various bisphosphonate agents and a range of adverse CV events. We conducted several pre-specified subgroup analyses to identify treatment effect heterogeneity and sensitivity analyses to assess the impact of study quality, influential studies, and publication bias. The results were consistent across these analyses. Since we only included RCTs, confounding or healthy user bias is unlikely.</p>
<p>There are also important limitations. A major challenge in conducting a systematic review that evaluates treatment-related adverse events is to find complete endpoints.[<xref rid="pone.0122646.ref035" ref-type="bibr">35</xref>] Because adverse CV events were rare and not anticipated at the time of conducting these trials, CV event data were available in only 58 of 170 eligible trials. Most of the excluded trials due to lack of CV data probably had very few or no events. As a result, our absolute risks of CV events might have been overestimated. On the other hand, incomplete surveillance and lack of adjudication for CV events in blinded trials might have caused non-differential misclassification of CV event status. Such outcome misclassification and intention-to-treat analysis for adverse events may have decreased statistical power to detect a small risk. In addition, most trials included generally healthy adults, which can limit the generalizability of our findings to patients with high burden of CV risk factors and comorbidities. Lastly, we had limited ability to assess the CV effects of less-commonly used bisphosphonates (e.g. etidronate and pamidronate) and in some subgroups.</p>
<p>Since the 2008 United States Food and Drug Administration update of safety review of bisphosphonates,[<xref rid="pone.0122646.ref053" ref-type="bibr">53</xref>] more studies have been published. Our meta-analysis indicates that commonly prescribed bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid) do not provide any clinically important benefits or harms on atherosclerotic CV events, but intravenous zoledronic acid may modestly increase the risk of atrial fibrillation. Considering the large reduction of osteoporotic fractures with bisphosphonates, changes in treatment decision for osteoporosis due to CV event risk are not justified. Whether less commonly prescribed agents (e.g. etidronate) prevent atherosclerotic CV events remains to be studied in future research.</p>
</sec>
<sec id="sec019">
<title>Supporting Information</title>
<supplementary-material id="pone.0122646.s001" xlink:href="info:doi/10.1371/journal.pone.0122646.s001" mimetype="application/msword" position="float" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0122646.s002" xlink:href="info:doi/10.1371/journal.pone.0122646.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>Text 1.</title>
<p>Systematic search strategy. <bold>Table 1.</bold> Characteristics of eligible randomized controlled trials by availability of cardiovascular event data. <bold>Table 2.</bold> Randomized controlled trials of bisphosphonates with available data on cardiovascular events. <bold>Table 3.</bold> Quality of included randomized controlled trials of bisphosphonates. <bold>Table 4.</bold> Number of adverse cardiovascular events by bisphosphonate dose. <bold>Table 5.</bold> Stratified analysis of bisphosphonates and adverse cardiovascular events by study quality. <bold>Fig 1. Assessment of study quality.</bold> Abbreviation: CV, cardiovascular. * Study quality was evaluated in the following 7 quality standards: 1) generation of random sequence, 2) concealment of allocation, 3) blinding of patients and personnel, 4) blinding of cardiovascular outcome assessors, 5) follow-up loss (&gt;20%) in the safety analysis, 6) completeness of cardiovascular outcome reporting, and 7) ascertainment of cardiovascular outcomes. <bold>Fig 2. Subgroup meta-analysis of total cardiovascular events associated with use of bisphosphonates.</bold> Abbreviations: CI, confidence interval; CV, cardiovascular; IV, intravenous; M-H, Mantel Haenszel; OR, odds ratio; PO, per os. * Heterogeneity by subgroup (P value for interaction) was assessed using meta-regression. <bold>Fig 3. Subgroup meta-analysis of atrial fibrillation associated with use of bisphosphonates.</bold> Abbreviations: CI, confidence interval; IV, intravenous; M-H, Mantel Haenszel; OR, odds ratio; PO, per os. * Heterogeneity by subgroup (P value for interaction) was assessed using meta-regression. <bold>Fig 4. Subgroup meta-analysis of myocardial infarction associated with use of bisphosphonates.</bold> Abbreviations: CI, confidence interval; IV, intravenous; M-H, Mantel Haenszel; OR, odds ratio; PO, per os. * Heterogeneity by subgroup (P value for interaction) was assessed using meta-regression. <bold>Fig 5. Subgroup meta-analysis of stroke associated with use of bisphosphonates.</bold> Abbreviations: CI, confidence interval; IV, intravenous; M-H, Mantel Haenszel; OR, odds ratio; PO, per os. * Heterogeneity by subgroup (P value for interaction) was assessed using meta-regression. <bold>Fig 6. Subgroup meta-analysis of cardiovascular death associated with use of bisphosphonates.</bold> Abbreviations: CI, confidence interval; CV, cardiovascular; IV, intravenous; M-H, Mantel Haenszel; OR, odds ratio; PO, per os. * Heterogeneity by subgroup (P value for interaction) was assessed using meta-regression.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0122646.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Looker</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Orwoll</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Johnston</surname> <given-names>CC</given-names> <suffix>Jr</suffix></name>, <name name-style="western"><surname>Lindsay</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Wahner</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Dunn</surname> <given-names>WL</given-names></name>, <etal>et al</etal>. <article-title>Prevalence of low femoral bone density in older U.S. adults from NHANES III</article-title>. <source>J Bone Miner Res</source> <year>1997</year>; <volume>12</volume>: <fpage>1761</fpage>–<lpage>1768</lpage>. <object-id pub-id-type="pmid">9383679</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kiel</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Kauppila</surname> <given-names>LI</given-names></name>, <name name-style="western"><surname>Cupples</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Hannan</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>O'Donnell</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>PW</given-names></name>, <etal>et al</etal>. <article-title>Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study</article-title>. <source>Calcif Tissue Int</source> <year>2001</year>; <volume>68</volume>: <fpage>271</fpage>–<lpage>276</lpage>. <object-id pub-id-type="pmid">11683533</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shaffer</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Kammerer</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Rainwater</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>O'Leary</surname> <given-names>DH</given-names></name>, <name name-style="western"><surname>Bruder</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Bauer</surname> <given-names>RL</given-names></name>, <etal>et al</etal>. <article-title>Decreased bone mineral density is correlated with increased subclinical atherosclerosis in older, but not younger, Mexican American women and men: the San Antonio Family Osteoporosis Study</article-title>. <source>Calcif Tissue Int</source> <year>2007</year>; <volume>81</volume>: <fpage>430</fpage>–<lpage>441</lpage>. <object-id pub-id-type="pmid">17992559</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barengolts</surname> <given-names>EI</given-names></name>, <name name-style="western"><surname>Berman</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kukreja</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Kouznetsova</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Chomka</surname> <given-names>EV</given-names></name>, <etal>et al</etal>. <article-title>Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women</article-title>. <source>Calcif Tissue Int</source> <year>1998</year>; <volume>62</volume>: <fpage>209</fpage>–<lpage>213</lpage>. <object-id pub-id-type="pmid">9501953</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van der Klift</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pols</surname> <given-names>HA</given-names></name>, <name name-style="western"><surname>Hak</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Witteman</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Hofman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>de Laet</surname> <given-names>CE</given-names></name>, <etal>et al</etal>. <article-title>Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study</article-title>. <source>Calcif Tissue Int</source> <year>2002</year>; <volume>70</volume>: <fpage>443</fpage>–<lpage>449</lpage>. <object-id pub-id-type="pmid">11976772</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>von der Recke</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Hassager</surname> <given-names>C</given-names></name>. <article-title>The association between low bone mass at the menopause and cardiovascular mortality</article-title>. <source>Am J Med</source> <year>1999</year>; <volume>106</volume>: <fpage>273</fpage>–<lpage>278</lpage>. <object-id pub-id-type="pmid">10190374</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kado</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Browner</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Blackwell</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gore</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Cummings</surname> <given-names>SR</given-names></name>. <article-title>Rate of bone loss is associated with mortality in older women: a prospective study</article-title>. <source>J Bone Miner Res</source> <year>2000</year>; <volume>15</volume>: <fpage>1974</fpage>–<lpage>1980</lpage>. <object-id pub-id-type="pmid">11028450</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Browner</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Seeley</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Vogt</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Cummings</surname> <given-names>SR</given-names></name>. <article-title>Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group</article-title>. <source>Lancet</source> <year>1991</year>; <volume>338</volume>: <fpage>355</fpage>–<lpage>358</lpage>. <object-id pub-id-type="pmid">1677708</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anagnostis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Karagiannis</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kakafika</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Tziomalos</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Athyros</surname> <given-names>VG</given-names></name>, <name name-style="western"><surname>Mikhailidis</surname> <given-names>DP</given-names></name>. <article-title>Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?</article-title> <source>Osteoporos Int</source> <year>2009</year>; <volume>20</volume>: <fpage>197</fpage>–<lpage>207</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00198-008-0648-5" xlink:type="simple">10.1007/s00198-008-0648-5</ext-link></comment> <object-id pub-id-type="pmid">18509713</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McFarlane</surname> <given-names>SI</given-names></name>, <name name-style="western"><surname>Muniyappa</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Shin</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Bahtiyar</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Sowers</surname> <given-names>JR</given-names></name>. <article-title>Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?</article-title> <source>Endocrine</source> <year>2004</year>; <volume>23</volume>: <fpage>1</fpage>–<lpage>10</lpage>. <object-id pub-id-type="pmid">15034190</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Demer</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Tintut</surname> <given-names>Y</given-names></name>. <article-title>Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2003</year>; <volume>23</volume>: <fpage>1739</fpage>–<lpage>1743</lpage>. <object-id pub-id-type="pmid">12958041</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schor</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Allen</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Canfield</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Sloan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Schor</surname> <given-names>SL</given-names></name>. <article-title>Pericytes derived from the retinal microvasculature undergo calcification in vitro</article-title>. <source>J Cell Sci</source> <year>1990</year>; <volume>97</volume>: <fpage>449</fpage>–<lpage>461</lpage>. <object-id pub-id-type="pmid">2074265</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Doherty</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Ashton</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Walsh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Beresford</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Grant</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Canfield</surname> <given-names>AE</given-names></name>. <article-title>Vascular pericytes express osteogenic potential in vitro and in vivo</article-title>. <source>J Bone Miner Res</source> <year>1998</year>; <volume>13</volume>: <fpage>828</fpage>–<lpage>838</lpage>. <object-id pub-id-type="pmid">9610747</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jeziorska</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>McCollum</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wooley</surname> <given-names>DE</given-names></name>. <article-title>Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries</article-title>. <source>Virchows Arch</source> <year>1998</year>; <volume>433</volume>: <fpage>559</fpage>–<lpage>565</lpage>. <object-id pub-id-type="pmid">9870690</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koshiyama</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Nakamura</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Minamikawa</surname> <given-names>J</given-names></name>. <article-title>Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source> <year>2000</year>; <volume>85</volume>: <fpage>2793</fpage>–<lpage>2796</lpage>. <object-id pub-id-type="pmid">10946883</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nitta</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Akiba</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Uchida</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Watanabe</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Majima</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis</article-title>. <source>Am J Kidney Dis</source> <year>2004</year>; <volume>44</volume>: <fpage>680</fpage>–<lpage>688</lpage>. <object-id pub-id-type="pmid">15384019</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kawahara</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nishikawa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kawahara</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Inazu</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Sakai</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>G</given-names></name>. <article-title>Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial</article-title>. <source>Circulation</source> <year>2013</year>; <volume>127</volume>: <fpage>2327</fpage>–<lpage>2335</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.113.001534" xlink:type="simple">10.1161/CIRCULATIONAHA.113.001534</ext-link></comment> <object-id pub-id-type="pmid">23658438</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Keller</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>HC</given-names></name>. <article-title>A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke</article-title>. <source>Osteoporos Int</source> <year>2012</year>; <volume>23</volume>: <fpage>2551</fpage>–<lpage>2557</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00198-012-1894-0" xlink:type="simple">10.1007/s00198-012-1894-0</ext-link></comment> <object-id pub-id-type="pmid">22270858</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Keller</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>HC</given-names></name>. <article-title>Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study</article-title>. <source>Osteoporos Int</source> <year>2013</year>; <volume>24</volume>: <fpage>271</fpage>–<lpage>277</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00198-012-2213-5" xlink:type="simple">10.1007/s00198-012-2213-5</ext-link></comment> <object-id pub-id-type="pmid">23152093</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wolfe</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bolster</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>O'Connor</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Michaud</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lyles</surname> <given-names>KW</given-names></name>, <name name-style="western"><surname>Colon-Emeric</surname> <given-names>CS</given-names></name>. <article-title>Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis</article-title>. <source>J Bone Miner Res</source> <year>2013</year>; <volume>28</volume>: <fpage>984</fpage>–<lpage>991</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jbmr.1792" xlink:type="simple">10.1002/jbmr.1792</ext-link></comment> <object-id pub-id-type="pmid">23074131</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Santos</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Cavalcanti</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Bandeira</surname> <given-names>FA</given-names></name>. <article-title>Vascular effects of bisphosphonates-a systematic review</article-title>. <source>Clin Med Insights Endocrinol Diabetes</source> <year>2012</year>; <volume>5</volume>: <fpage>47</fpage>–<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4137/CMED.S10007" xlink:type="simple">10.4137/CMED.S10007</ext-link></comment> <object-id pub-id-type="pmid">23133318</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fiore</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Pennisi</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Pulvirenti</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Francucci</surname> <given-names>CM</given-names></name>. <article-title>Bisphosphonates and atherosclerosis</article-title>. <source>J Endocrinol Invest</source> <year>2009</year>; <volume>32</volume>: <fpage>38</fpage>–<lpage>43</lpage>. <object-id pub-id-type="pmid">19724165</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Black</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Delmas</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Eastell</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Reid</surname> <given-names>IR</given-names></name>, <name name-style="western"><surname>Boonen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cauley</surname> <given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>356</volume>: <fpage>1809</fpage>–<lpage>1822</lpage>. <object-id pub-id-type="pmid">17476007</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cummings</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Schwartz</surname> <given-names>AV</given-names></name>, <name name-style="western"><surname>Black</surname> <given-names>DM</given-names></name>. <article-title>Alendronate and atrial fibrillation</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>356</volume>: <fpage>1895</fpage>–<lpage>1896</lpage>. <object-id pub-id-type="pmid">17476024</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Ho</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Cheak</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Lau</surname> <given-names>CS</given-names></name>. <article-title>Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies</article-title>. <source>BMC Musculoskelet Disord</source> <year>2009</year>; <volume>10</volume>: <fpage>113</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2474-10-113" xlink:type="simple">10.1186/1471-2474-10-113</ext-link></comment> <object-id pub-id-type="pmid">19772579</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sharma</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Chatterjee</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Arbab-Zadeh</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Goyal</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lichstein</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ghosh</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis</article-title>. <source>Chest</source> <year>2013</year>; <volume>144</volume>: <fpage>1311</fpage>–<lpage>1322</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.13-0675" xlink:type="simple">10.1378/chest.13-0675</ext-link></comment> <object-id pub-id-type="pmid">23722644</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sharma</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Einstein</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Vallakati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Arbab-Zadeh</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Walker</surname> <given-names>MD</given-names></name>, <name name-style="western"><surname>Mukherjee</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Risk of atrial fibrillation with use of oral and intravenous bisphosphonates</article-title>. <source>Am J Cardiol</source> <year>2014</year>; <volume>113</volume>: <fpage>1815</fpage>–<lpage>1821</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjcard.2014.03.008" xlink:type="simple">10.1016/j.amjcard.2014.03.008</ext-link></comment> <object-id pub-id-type="pmid">24837258</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Howard</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Barnes</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Vacek</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>SM</given-names></name>. <article-title>Impact of bisphosphonates on the risk of atrial fibrillation</article-title>. <source>Am J Cardiovasc Drugs</source> <year>2010</year>; <volume>10</volume>: <fpage>359</fpage>–<lpage>367</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2165/11584720-000000000-00000" xlink:type="simple">10.2165/11584720-000000000-00000</ext-link></comment> <object-id pub-id-type="pmid">21090829</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Cadarette</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Solomon</surname> <given-names>DH</given-names></name>. <article-title>Bisphosphonates and risk of atrial fibrillation: a meta-analysis</article-title>. <source>Arthritis Res Ther</source> <year>2010</year>; <volume>12</volume>: <fpage>R30</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/ar2938" xlink:type="simple">10.1186/ar2938</ext-link></comment> <object-id pub-id-type="pmid">20170505</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Loke</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Jeevanantham</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Singh</surname> <given-names>S</given-names></name>. <article-title>Bisphosphonates and atrial fibrillation: systematic review and meta-analysis</article-title>. <source>Drug Saf</source> <year>2009</year>; <volume>32</volume>: <fpage>219</fpage>–<lpage>228</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2165/00002018-200932030-00004" xlink:type="simple">10.2165/00002018-200932030-00004</ext-link></comment> <object-id pub-id-type="pmid">19338379</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barrett-Connor</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Swern</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Hustad</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Bone</surname> <given-names>HG</given-names></name>, <name name-style="western"><surname>Liberman</surname> <given-names>UA</given-names></name>, <name name-style="western"><surname>Papapoulos</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials</article-title>. <source>Osteoporos Int</source> <year>2012</year>; <volume>23</volume>: <fpage>233</fpage>–<lpage>245</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00198-011-1546-9" xlink:type="simple">10.1007/s00198-011-1546-9</ext-link></comment> <object-id pub-id-type="pmid">21369791</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lewiecki</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Cooper</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hartl</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mehta</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Papapoulos</surname> <given-names>SE</given-names></name>, <etal>et al</etal>. <article-title>Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials</article-title>. <source>Int J Clin Pract</source> <year>2010</year>; <volume>64</volume>: <fpage>821</fpage>–<lpage>826</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1742-1241.2010.02335.x" xlink:type="simple">10.1111/j.1742-1241.2010.02335.x</ext-link></comment> <object-id pub-id-type="pmid">20337751</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karam</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Camm</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>McClung</surname> <given-names>M</given-names></name>. <article-title>Yearly zoledronic acid in postmenopausal osteoporosis</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>357</volume>: <fpage>712</fpage>–<lpage>713</lpage>. <object-id pub-id-type="pmid">17703529</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhuriya</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Singh</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Molnar</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Arora</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Khosla</surname> <given-names>S</given-names></name>. <article-title>Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis</article-title>. <source>Int J Cardiol</source> <year>2010</year>; <volume>142</volume>: <fpage>213</fpage>–<lpage>217</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijcard.2009.11.041" xlink:type="simple">10.1016/j.ijcard.2009.11.041</ext-link></comment> <object-id pub-id-type="pmid">20051297</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Derry</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>LY</given-names></name>, <name name-style="western"><surname>Aronson</surname> <given-names>JK</given-names></name>. <article-title>Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials</article-title>. <source>BMC Med Res Methodol</source> <year>2001</year>; <volume>1</volume>: <fpage>7</fpage>. <object-id pub-id-type="pmid">11591220</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bradburn</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Berlin</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Russell</surname> <given-names>Localio A</given-names></name>. <article-title>Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events</article-title>. <source>Stat Med</source> <year>2007</year>; <volume>26</volume>: <fpage>53</fpage>–<lpage>77</lpage>. <object-id pub-id-type="pmid">16596572</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>: <fpage>1539</fpage>–<lpage>1558</lpage>. <object-id pub-id-type="pmid">12111919</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <year>1994</year>; <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>Bmj</source> <year>1997</year>; <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lyles</surname> <given-names>KW</given-names></name>, <name name-style="western"><surname>Colon-Emeric</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Magaziner</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Adachi</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Pieper</surname> <given-names>CF</given-names></name>, <name name-style="western"><surname>Mautalen</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Zoledronic acid and clinical fractures and mortality after hip fracture</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>357</volume>: <fpage>1799</fpage>–<lpage>1809</lpage>. <object-id pub-id-type="pmid">17878149</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Celiloglu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aydin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Balci</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kolamaz</surname> <given-names>T</given-names></name>. <article-title>The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis</article-title>. <source>Menopause</source> <year>2009</year>; <volume>16</volume>: <fpage>689</fpage>–<lpage>693</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/gme.0b013e318194cafd" xlink:type="simple">10.1097/gme.0b013e318194cafd</ext-link></comment> <object-id pub-id-type="pmid">19240658</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kanazawa</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hayashi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takase</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Shimizu</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Sugimoto</surname> <given-names>T</given-names></name>. <article-title>Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis</article-title>. <source>Am J Med Sci</source> <year>2010</year>; <volume>339</volume>: <fpage>519</fpage>–<lpage>524</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MAJ.0b013e3181db6dfe" xlink:type="simple">10.1097/MAJ.0b013e3181db6dfe</ext-link></comment> <object-id pub-id-type="pmid">20400887</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hollander</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Paddock</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nagraj</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Colombo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kirkpatrick</surname> <given-names>B</given-names></name>. <article-title>Effects of anticalcifying and antifibrobrotic drugs on pre-established atherosclerosis in the rabbit</article-title>. <source>Atherosclerosis</source> <year>1979</year>; <volume>33</volume>: <fpage>111</fpage>–<lpage>123</lpage>. <object-id pub-id-type="pmid">111683</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jackson</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Gee</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Guyon-Gellin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Niesor</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Bentzen</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Kerns</surname> <given-names>WD</given-names></name>, <etal>et al</etal>. <article-title>Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i)</article-title>. <source>Arzneimittelforschung</source> <year>2000</year>; <volume>50</volume>: <fpage>380</fpage>–<lpage>386</lpage>. <object-id pub-id-type="pmid">10800637</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ylitalo</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Oksala</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Yla-Herttuala</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ylitalo</surname> <given-names>P</given-names></name>. <article-title>Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits</article-title>. <source>J Lab Clin Med</source> <year>1994</year>; <volume>123</volume>: <fpage>769</fpage>–<lpage>776</lpage>. <object-id pub-id-type="pmid">8195683</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ikeda</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yamada</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Matsui</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sawada</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nakamura</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study)</article-title>. <source>Eur J Prev Cardiol</source> <year>2013</year>; <volume>20</volume>: <fpage>1069</fpage>–<lpage>1079</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/2047487312451539" xlink:type="simple">10.1177/2047487312451539</ext-link></comment> <object-id pub-id-type="pmid">22689416</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Crouse</surname> <given-names>JR</given-names> <suffix>3rd</suffix></name>, <name name-style="western"><surname>Raichlen</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Riley</surname> <given-names>WA</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>GW</given-names></name>, <name name-style="western"><surname>Palmer</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>O'Leary</surname> <given-names>DH</given-names></name>, <etal>et al</etal>. <article-title>Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial</article-title>. <source>JAMA</source> <year>2007</year>; <volume>297</volume>: <fpage>1344</fpage>–<lpage>1353</lpage>. <object-id pub-id-type="pmid">17384434</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Toussaint</surname> <given-names>ND</given-names></name>, <name name-style="western"><surname>Lau</surname> <given-names>KK</given-names></name>, <name name-style="western"><surname>Strauss</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Polkinghorne</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Kerr</surname> <given-names>PG</given-names></name>. <article-title>Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial</article-title>. <source>Am J Kidney Dis</source> <year>2010</year>; <volume>56</volume>: <fpage>57</fpage>–<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.ajkd.2009.12.039" xlink:type="simple">10.1053/j.ajkd.2009.12.039</ext-link></comment> <object-id pub-id-type="pmid">20347511</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tanko</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Alexandersen</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Bagger</surname> <given-names>YZ</given-names></name>, <name name-style="western"><surname>Christiansen</surname> <given-names>C</given-names></name>. <article-title>Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women</article-title>. <source>Osteoporos Int</source> <year>2005</year>; <volume>16</volume>: <fpage>184</fpage>–<lpage>190</lpage>. <object-id pub-id-type="pmid">15197541</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Blumenthal</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Kapur</surname> <given-names>NK</given-names></name>. <article-title>Can a potent statin actually regress coronary atherosclerosis?</article-title> <source>JAMA</source> <year>2006</year>; <volume>295</volume>: <fpage>1583</fpage>–<lpage>1584</lpage>. <object-id pub-id-type="pmid">16533937</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>D'Ascenzo</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Agostoni</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Abbate</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Castagno</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lipinski</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Vetrovec</surname> <given-names>GW</given-names></name>, <etal>et al</etal>. <article-title>Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials</article-title>. <source>Atherosclerosis</source> <year>2013</year>; <volume>226</volume>: <fpage>178</fpage>–<lpage>185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.atherosclerosis.2012.10.065" xlink:type="simple">10.1016/j.atherosclerosis.2012.10.065</ext-link></comment> <object-id pub-id-type="pmid">23206978</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pazianas</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Compston</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>CL</given-names></name>. <article-title>Atrial fibrillation and bisphosphonate therapy</article-title>. <source>J Bone Miner Res</source> <year>2010</year>; <volume>25</volume>: <fpage>2</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1359/jbmr.091201" xlink:type="simple">10.1359/jbmr.091201</ext-link></comment> <object-id pub-id-type="pmid">20091928</object-id></mixed-citation></ref>
<ref id="pone.0122646.ref053"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">The US Food and Drug Administration. Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates.</mixed-citation></ref>
</ref-list>
</back>
</article>